Indications for XOFLUZA:
Treatment of acute uncomplicated influenza in patients who have been symptomatic for no more than 48hrs and who are otherwise healthy, or at high risk of developing influenza-related complications. Post-exposure prophylaxis of influenza following contact with an individual who has influenza.
Limitations of Use:
Consider available information on drug susceptibility patterns for circulating influenza strains when deciding whether to use.
Start within 48hrs of symptom onset or exposure to influenza. ≥12yrs (<80kg): 40mg as a single dose; (≥80kg): 80mg as a single dose.
<12yrs: not established.
Potential secondary bacterial infections; treat appropriately. Pregnancy. Nursing mothers.
Polymerase acidic (PA) endonuclease inhibitor.
Avoid co-administration with dairy products, calcium-fortified beverages, polyvalent cation-containing laxatives, antacids, or oral supplements (eg, calcium, iron, magnesium, selenium, or zinc). May reduce efficacy of live attenuated influenza vaccines.
Diarrhea, bronchitis, nausea, sinusitis, headache; hypersensitivity reactions.
Generic Drug Availability: